TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21218747

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (initial dose of 80 mg, followed by 8 mg/h infusion)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous ranitidine (100 mg bolus, followed by 100 mg boluses every 6 hours for 72 hours)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 108
Study: 18523394

Group type: EXPERIMENTAL
Intervention: Radiographic esophageal imaging by oral administration of contrast media
Number of subjects: 468

Group type: COMPARATOR
Intervention: Ross technique (control group)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 468
Study: 15926017

Group type: EXPERIMENTAL
Intervention: Amitriptyline 10 mg daily for two months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intra-oral device appliance for two months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 18
Study: 12683743

Group type: EXPERIMENTAL
Intervention: HIV Harm Reduction Program (HHRP+)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Active control with harm reduction components recommended by the National AIDS Demonstration Research Project
Number of subjects: 90
Study: 10340911

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg once daily for 14 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (poor metabolizers)
Number of subjects: 9
Study: 7569455

Group type: EXPERIMENTAL
Intervention: 30 micrograms of estrogen and 300 micrograms of progestogen (Group 2)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 35 micrograms of estrogen and 500 micrograms of progestogen (Group 3)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 30 micrograms of levonorgestrel followed by intrauterine device or contraceptives of group 2 or group 3 (Group 4)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (Group 1)
Number of subjects: 371
Study: 1775605

Group type: EXPERIMENTAL
Intervention: Arecoline at 4 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 399858

Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder (200 micrograms per capsule)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Salbutamol aerosol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rotahaler (device for powder administration)
Number of subjects: 38
Study: 31439599

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Levocetirizine and prednisone
Number of subjects: 240
Study: 27469608

Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (IJV) CVC placement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Left internal jugular vein (IJV) CVC placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative assessment using chest radiography (CXR)
Number of subjects: 60
Study: 25996371

Group type: EXPERIMENTAL
Intervention: Internet plus culturally tailored text message group
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (Internet physical activity program)
Number of subjects: 252
Study: 22791300

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at PC-6 acupuncture points before HUT/LBNP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at PC-6 acupuncture points during HUT/LBNP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) at a non-acupoint
Number of subjects: 30

Group type: COMPARATOR
Intervention: No electroacupuncture (control group)
Number of subjects: 30
Study: 21044863

Group type: EXPERIMENTAL
Intervention: pLCHS‐hph vector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pChG‐bar vector
Number of subjects: 0
Study: 19917927

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy (CRT)
Number of subjects: 49
Study: 16460916

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 14991626

Group type: EXPERIMENTAL
Intervention: Prosthetic mesh placed in a sublay position
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional stoma
Number of subjects: 54
Study: 11277642

Group type: COMPARATOR
Intervention: Carboplatin alone (300 mg/m2 every 28 days for five cycles)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Carboplatin plus epidoxorubicin (120 mg/m2 and 300 mg/m2 every 28 days for five cycles)
Number of subjects: 190
Study: 11229179

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 32
Study: 8371471

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic agents
Number of subjects: 98000

Group type: EXPERIMENTAL
Intervention: Beta-blockers (class II agents)
Number of subjects: 98000

Group type: EXPERIMENTAL
Intervention: Amiodarone (class III agent)
Number of subjects: 98000

Group type: EXPERIMENTAL
Intervention: Class IV agents (calcium channel blockers)
Number of subjects: 98000
Study: 3088642

Group type: COMPARATOR
Intervention: 0% THC marijuana cigarettes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.01% THC marijuana cigarettes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.84% THC marijuana cigarettes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2.84% THC marijuana cigarettes
Number of subjects: 7
Study: 29334277

Group type: EXPERIMENTAL
Intervention: DPOAE screening conducted by village health workers (VHWs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tele‐ABR (gold standard)
Number of subjects: 119
Study: 27604619

Group type: EXPERIMENTAL
Intervention: Early comprehensive patient care (ECPC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard patient care (SPC)
Number of subjects: 183
Study: 24799649

Group type: EXPERIMENTAL
Intervention: Hand sanitizer dispenser present on the anesthesia machine
Number of subjects: 40

Group type: COMPARATOR
Intervention: No hand sanitizer dispenser present
Number of subjects: 40
Study: 23082391

Group type: EXPERIMENTAL
Intervention: Restored with resin composite using total acid etch adhesive technique (37% H3PO4 + Single Bond + Z250)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Restored with resin composite but without acid etching (Single Bond + Z250)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sound blocks (control group)
Number of subjects: 10
Study: 20106932

Group type: EXPERIMENTAL
Intervention: High red meat diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined red meat/fish diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High fish diet
Number of subjects: 14
Study: 16670695

Group type: EXPERIMENTAL
Intervention: High glycemic load breakfast meal (farina)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low glycemic load breakfast meal (fiber-loop cereal with psyllium)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standardized lunch after both breakfast types
Number of subjects: 45
Study: 14967281

Group type: EXPERIMENTAL
Intervention: Straight microtip
Number of subjects: 48

Group type: COMPARATOR
Intervention: Kelman microtip
Number of subjects: 48
Study: 11371732

Group type: EXPERIMENTAL
Intervention: Systemic-enteric (SE) drainage
Number of subjects: 54

Group type: COMPARATOR
Intervention: Portal-enteric (PE) drainage
Number of subjects: 54
Study: 9209898

Group type: EXPERIMENTAL
Intervention: Vaginal estriol (0.5 mg daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol (0.05 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study: 8272550

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (CDP, 2 cycles) followed by radical surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional radiotherapy (ERT 45 Gy + IRT or END-RT 20-25 Gy)
Number of subjects: 54
Study: 3040605

Group type: EXPERIMENTAL
Intervention: Enalapril (5-10 mg twice daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 29302858

Group type: EXPERIMENTAL
Intervention: Eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8
Number of subjects: 392

Group type: COMPARATOR
Intervention: Capecitabine 1.25 g/m2 orally twice daily on days 1-14 (21-day cycles)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Number of subjects: 392

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 392
Study: 26283647

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standardized seated heel‐rises
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Single-leg standing heel‐rises
Number of subjects: 93
Study: 24584818

Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle intervention (9 monthly telephone calls to patients and spouses)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 251
Study: 22433632

Group type: EXPERIMENTAL
Intervention: Use of wireless phones
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Different phone types (calculated separately)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Cumulative use divided into three groups (1‐1000, 1001‐2000 and >2000 h)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Use of wireless phones (light-to-moderate)
Number of subjects: 331
Study: 20507841

Group type: EXPERIMENTAL
Intervention: Diclofenac 3% gel treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study: 18826094

Group type: EXPERIMENTAL
Intervention: Sonographically guided percutaneous ethanol injection (4 injections on average in the first group, 6 injections in the second group, 2-10 ml ethanol per injection)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sonographically guided percutaneous ethanol injection (6 injections)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study: 15975536

Group type: COMPARATOR
Intervention: 7-day triple therapy with esomeprazole 20mg b.i.d., clarithromycin 500 mg b.i.d. and amoxycillin 1g b.i.d.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Quadruple therapy comprising of the same regimen plus lactoferrin 200mg b.i.d.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Side effects following triple regimen
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Side effects following quadruple regimen
Number of subjects: 133
Study: 15333416

Group type: EXPERIMENTAL
Intervention: Adenosine (50 microg. kg(‐1). min(‐1)) infused IV over 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infused IV over 60 min
Number of subjects: 20
Study: 11301934

Group type: EXPERIMENTAL
Intervention: Diet rich in rapeseed oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet rich in saturated fat
Number of subjects: 20
Study: 9249934

Group type: EXPERIMENTAL
Intervention: Dual therapy (tacrolimus 0.10 mg/kg and prednisolone)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Triple therapy (tacrolimus 0.06 mg/kg, prednisolone, and azathioprine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 130
Study: 8388030

Group type: EXPERIMENTAL
Intervention: Alpha-interferon preparations (exact dosage and duration not specified)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (20 nuns with no lifetime sexual exposure)
Number of subjects: 42
Study: 3434169

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 60
Study: 29462266

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin 600 mg once daily for 5 days
Number of subjects: 0
Study: 28579233

Group type: EXPERIMENTAL
Intervention: Vaccine with 120μg RSV F protein and 0.4mg aluminum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of 60μg RSV F protein and 0.8mg aluminum
Number of subjects: 0

Group type: COMPARATOR
Intervention: All formulations (including placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active vaccinees
Number of subjects: 0
Study: 25647729

Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonoxynol-9 2% gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study: 24127924

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) 1200-1800 mL/day, twice daily for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 60
Study: 21168920

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 225

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 225
Study: 18081359

Group type: EXPERIMENTAL
Intervention: Bio‐HA
Number of subjects: 321

Group type: COMPARATOR
Intervention: hylan G‐F 20
Number of subjects: 321
Study: 16812974

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg
Number of subjects: 8888
Study: 12962763

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 240
Study: 10661482

Group type: EXPERIMENTAL
Intervention: rhEPO therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: No rhEPO therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (10 mg, 3 times a week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Folic acid deficiency
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of controls and dialyzed patients on rhEPO therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation between serum erythropoietin and folic acid levels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation between folic acid and homocysteine levels
Number of subjects: 27
Study: 8713770

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 948

Group type: COMPARATOR
Intervention: Non-aprotinin (Control)
Number of subjects: 948
Study: 1432502

Group type: EXPERIMENTAL
Intervention: Indirect ophthalmoscope and protractor method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 20
Study: 3881242

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 334

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 334

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 334
Study: 30813779

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 40
Study: 30948622

Group type: EXPERIMENTAL
Intervention: Capillary-flow data-independent acquisition (DIA) mass spectrometry
Number of subjects: 1508
Study: 29153873

Group type: EXPERIMENTAL
Intervention: BeatIt (behavioural activation intervention)
Number of subjects: 161

Group type: COMPARATOR
Intervention: StepUp (guided self-help intervention)
Number of subjects: 161
Study: 25499305

Group type: EXPERIMENTAL
Intervention: ELA + PTA
Number of subjects: 250

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 250
Study: 23452711

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT), used twice a day for two months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 35
Study: 21105846

Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endofill
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (gutta‐percha cone only)
Number of subjects: 40
Study: 18848470

Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulphate once daily for 2 years
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo once daily for 2 years
Number of subjects: 222
Study: 17128343

Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC)
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) among HIV-infected women
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-infected women
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) among HIV-uninfected women
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-uninfected women
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) followed by metronidazole plus vaginal clotrimazole (MC) as second-line treatment
Number of subjects: 1570
Study: 15090119

Group type: EXPERIMENTAL
Intervention: All Stars program
Number of subjects: 14
Study: 11721720

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (10 mg bolus + 10 mg/hour for 3 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 9207470

Group type: EXPERIMENTAL
Intervention: CD19+ B cells
Number of subjects: 521
Study: 8256988

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1700 mg of calcium carbonate daily)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Estrogen-progesterone-calcium (0.625 mg conjugated equine estrogens, 10 mg progesterone, and 1700 mg elemental calcium daily)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 3300974

Group type: EXPERIMENTAL
Intervention: isosorbide 5‐mononitrate (acute administration)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: isosorbide 5‐mononitrate (2 months treatment, 20 mg three times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo (acute administration)
Number of subjects: 14
Study: 31914620

Group type: EXPERIMENTAL
Intervention: Exercise twice-a-day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily exercise
Number of subjects: 0
Study: 31129103

Group type: EXPERIMENTAL
Intervention: Hua-Shan Grading of Upper Extremity (H-S grading)
Number of subjects: 64
Study: 27988144

Group type: EXPERIMENTAL
Intervention: EUC plus CAP
Number of subjects: 377
Study: 24584608

Group type: EXPERIMENTAL
Intervention: Straight Tenckhoff catheters (SCs)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Coiled Tenckhoff catheters (CCs)
Number of subjects: 189
Study: 24088004

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 80

Group type: COMPARATOR
Intervention: No educational program
Number of subjects: 80
Study: 21632455

Group type: EXPERIMENTAL
Intervention: Actual tumor measurements (TM) at 12 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: WHO criteria (three-level) at 12 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: WHO criteria (two-level) at 12 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Actual TM at 24 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: WHO criteria (three-level) at 24 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: WHO criteria (two-level) at 24 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Actual TM in patients with WHO status of response at 12 weeks
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Actual TM in patients with stable disease or progression at 12 weeks
Number of subjects: 1188
Study: 19225758

Group type: EXPERIMENTAL
Intervention: Regular passive ROM exercise (PROME) by a physical therapist
Number of subjects: 50

Group type: COMPARATOR
Intervention: No PROME (control knee)
Number of subjects: 50
Study: 16681817

Group type: EXPERIMENTAL
Intervention: Luliconazole 1% cream applied once a day for 2 weeks, followed by placebo for 2 weeks.
Number of subjects: 511

Group type: COMPARATOR
Intervention: Bifonazole 1% cream applied once a day for 4 weeks.
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Luliconazole 1% cream
Number of subjects: 511

Group type: COMPARATOR
Intervention: Bifonazole 1% cream
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 511
Study: 15080791

Group type: EXPERIMENTAL
Intervention: BXL-628
Number of subjects: 0
Study: 12434826

Group type: EXPERIMENTAL
Intervention: Touch (forearm touched for 1 to 2 seconds)
Number of subjects: 227

Group type: COMPARATOR
Intervention: No touch (forearm not touched)
Number of subjects: 227
Study: 9771305

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 100 micrograms kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 8554863

Group type: EXPERIMENTAL
Intervention: Counseling and/or discussion for newly detected problems
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Counseling and/or discussion for known problems
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Referral for further management for newly detected problems
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Referral for further management for known problems
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Clinical assessment of health status
Number of subjects: 249
Study: 2375514

Group type: EXPERIMENTAL
Intervention: Halothane in O2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Halothane with 25% N2O
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Halothane with 50% N2O
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Halothane with 75% N2O
Number of subjects: 51